JCR Pharmaceuticals and Acumen Pharmaceuticals Forge Strategic Partnership to Develop a Blood-Brain Barrier-Penetrating Alzheimer’s Therapy Using J-Brain Cargo® Platform JCR Pharmaceuticals Co., Ltd. (TSE: 4552), a Japan-based global specialty biopharmaceutical company renowned for its focus on rare and genetic diseases,…
New Guidelines Expand Access to Advanced Liver Imaging and Transplant Evaluations Using Contrast-Enhanced Ultrasound A new policy change is being hailed by medical experts as a transformative advancement in the diagnosis and management of liver disease, particularly for patients suffering…
Baxdrostat Achieves Positive Results in Phase III BaxHTN Trial, Demonstrating Significant Blood Pressure Reduction in Patients with Uncontrolled or Resistant Hypertension AstraZeneca has announced promising top-line results from its pivotal Phase III BaxHTN clinical trial evaluating the efficacy and safety…
WHO’s International Pathogen Surveillance Network Launches Communities of Practice to Advance Genomic Surveillance The World Health Organization’s (WHO) Hub for Pandemic and Epidemic Intelligence has taken a major step forward in strengthening global health preparedness through the International Pathogen Surveillance…
Burundi Eliminates Trachoma as a Public Health Problem, Marking Major Milestone in Disease Control The World Health Organization (WHO) has officially validated that Burundi has eliminated trachoma as a public health problem, becoming the eighth country in the WHO African…
WHO-WIPO-WTO Webinar Highlights Role of Public Procurement in Advancing Global Health Equity and Innovation On July 3, 2025, the World Health Organization (WHO), the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO) jointly hosted a technical webinar…
Capricor Shares Tumble After FDA Rejects Cell Therapy for Duchenne Cardiomyopathy Over Efficacy Concerns Capricor Therapeutics suffered a major regulatory setback Friday after the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) rejecting its investigational cell…
The FDA’s surprise release of 200 complete response letters (CRLs) offered a rare glimpse into the inner workings of the agency’s decision-making—and the winding paths some drugs took to eventually reach the market. Among the disclosures were rejections for now-approved…
European Commission Approves TEVIMBRA® (Tislelizumab) with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma BeOne Medicines Ltd., a global biotechnology company dedicated to oncology innovation, today announced that the European Commission (EC) has granted marketing authorization for TEVIMBRA®…
Bayer Secures German Operations Until 2030 with New Agreement, Plans Structured Exit from Frankfurt Site In a significant development for its workforce and long-term operational strategy in Germany, Bayer AG has reached a landmark agreement with employee representatives on the…
Biogen and Stoke Present New Zorevunersen Data Supporting Phase 3 Dravet Syndrome Study Biogen and Stoke Therapeutics, Inc. (Nasdaq: STOK) today presented new data supporting the design and dosing strategy of the ongoing Phase 3 EMPEROR study of zorevunersen, an…
BeOne, a global oncology company, today announced that the European Commission has approved TEVIMBRA® (tislelizumab) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC) not suitable for curative surgery…
